Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.

Michael Thomas SchweizerRoman GulatiMallory BeightolEric Q KonnickHeather H ChengNola KlemfussNavonil De SarkarEvan Y YuR Bruce MontgomeryPeter S NelsonColin C Pritchard

Published in: The Prostate (2019)

Disease burden, including a PSA >10 ng/mL, is strongly associated with detecting somatic mutations from cfDNA specimens.

Keyphrases

circulating tumor
prostate cancer
cell free
radical prostatectomy
circulating tumor cells
risk factors
gene expression
single molecule
fine needle aspiration
data analysis